Literature DB >> 12651264

Expression of recombination activating genes-1 and-2 immunoglobulin heavy chain gene rearrangements in acute myeloid leukemia: evaluation of biological and clinical significance in a series of 76 uniformly treated patients and review of the literature.

Niki Stavroyianni1, Chrysoula Belessi, Kostas Stamatopoulos, Christos Kosmas, George Paterakis, Danae Abazis, Constantinos Pangalos, Xenophon Yataganas.   

Abstract

BACKGROUND AND OBJECTIVES: Early lymphoid differentiation is characterized by antigen receptor gene rearrangements; the rearrangement process is governed by two lymphoid-specific genes, RAG (recombinase activating gene)-1 and -2. The available data on the incidence and prognostic significance of clonal immunoglobulin heavy chain (IgH) gene rearrangements in acute myeloid leukemia (AML) are rather contradictory. The aim of this study was to evaluate the incidence and prognostic significance of RAG-1 and -2 mRNA transcripts and clonal IgH gene rearrangements in a cohort of uniformly treated AML patients; the available literature is also reviewed. DESIGN AND METHODS: The study was performed on 76 AML patients, newly diagnosed between August 1996 and November 1999. RAG-1/-2 gene expression was analyzed by a reverse transcriptase polymerase chain reaction technique and IgH gene rearrangements were detected with variable region (VH) family-specific and consensus framework region (FWR)-2 and/or-3 primers. Statistical associations were explored between IgH monoclonality/ RAG mRNA expression and: (i) age, gender, FAB subtype, immunophenotype, cytogenetic risk groups; (ii) response variables (response/relapse incidence, survival).
RESULTS: In total, 38/75 samples (50.6%) were RAG-1 and/or -2 positive; 30/76 samples (39.5%) carried clonal IgH genes, whereas 13/30 IgH-positive samples (43.3%) were RAG-1/2-negative. Significant associations were detected only for RAG-2 positivity and unfavorable karyotype and IgH monoclonality and FAB subtypes M4/ M5; no association was identified with response outcome and survival. INTERPRETATION AND
CONCLUSIONS: Lymphoid-specific molecular markers are detected in a significant proportion of AML patients, regardless of differentiation status (assessed morphologically/ immunophenotypically); however, in our experience, they do not seem to constitute an adverse prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651264

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  3 in total

1.  The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker.

Authors:  Sotirios G Papageorgiou; Christos K Kontos; Vassiliki Pappa; Hellinida Thomadaki; Frida Kontsioti; John Dervenoulas; Efstathios Papageorgiou; Theofanis Economopoulos; Andreas Scorilas
Journal:  Oncologist       Date:  2011-07-07

2.  NUCKS overexpression in breast cancer.

Authors:  Yiannis Drosos; Mirsini Kouloukoussa; Anne Carine Østvold; Kirsten Grundt; Nikos Goutas; Dimitrios Vlachodimitropoulos; Sophia Havaki; Panagoula Kollia; Christos Kittas; Evangelos Marinos; Vassiliki Aleporou-Marinou
Journal:  Cancer Cell Int       Date:  2009-08-10       Impact factor: 5.722

3.  Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.

Authors:  Philip Savage
Journal:  BMC Cancer       Date:  2015-01-21       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.